Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 9 peer-reviewed journal articles Updated
Nephrology

The Hematology Connection: Why Your Blood Matters

At a Glance

Immunotactoid glomerulopathy can be the first sign of a small blood-cell or immune-system problem. Hematology testing checks for abnormal proteins and cell clones, and repeat monitoring may be needed even when the first workup is negative.

When you are diagnosed with Immunotactoid Glomerulopathy (ITG), your care team will quickly expand beyond your kidney doctor (nephrologist). You will almost certainly be referred to a hematologist (a blood specialist).

This referral isn’t because you necessarily have blood cancer, but because ITG is often the first visible sign of an underlying issue in your bone marrow or immune system [1]. Your kidneys are reacting to abnormal proteins being produced elsewhere in your body.

Monoclonal vs. Polyclonal ITG

The first step in understanding your “hematology connection” is determining if your ITG is monoclonal or polyclonal. This is decided by looking at the light chains (Kappa and Lambda) stuck in your kidney biopsy.

  • Monoclonal ITG (approx. 67% of cases in one large series): This occurs when a single “clone” of abnormal B-cells or plasma cells produces one specific type of protein [1]. This version has the strongest link to blood disorders. In one large study, 53% of patients with monoclonal ITG were found to have a lymphoma [1].
  • Polyclonal ITG (approx. 33% of cases in the same series): In these cases, the protein deposits are a mix of different light chains. This is more commonly associated with autoimmune diseases, chronic infections (like Hepatitis C), or generalized immune activation, though it still requires a thorough blood workup [1][2].

Associated Conditions

ITG is frequently a symptom of one of the following conditions:

  • CLL and SLL: Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma are common blood conditions linked to ITG, found in about 41% of cases in one cohort [1].
  • MGRS: Monoclonal Gammopathy of Renal Significance is a term used when a small clone of cells produces a protein that is toxic to the kidney, but the clone does not meet the criteria for a blood cancer requiring its own treatment [3]. Even though it isn’t overt cancer, it is treated to save the kidney [3].
  • Multiple Myeloma: A more advanced plasma cell disorder found in about 6% of ITG patients in the cohort [1].

The Hematologic Workup

To find the source of the proteins, your hematologist will use several specific tests:

  1. SPEP and UPEP with Immunofixation: These tests look for an “M-spike,” a peak of abnormal protein in your blood or urine [4].
  2. Serum Free Light Chain (sFLC) Assay: A sensitive test that measures the ratio of Kappa to Lambda light chains in your blood [5].
  3. Flow Cytometry: A test that “scans” your blood cells to see if there is a cloned population [6].
  4. Bone Marrow Biopsy or Imaging: Depending on the suspected disorder, a sample of marrow or a scan may be taken to see if the abnormal cells are living there [7].

Why Monitoring Matters

It is common for the initial blood workup to be “negative” or “unrevealing.” A monoclonal biopsy pattern alone does not guarantee a detectable marrow or lymph-node clone. In some cases, the group of abnormal cells is simply too small to be detected by current tests [8].

There are documented cases where patients were diagnosed with ITG first, and a blood disorder—such as Diffuse Large B-cell Lymphoma—only became detectable later [8]. Because of this, even if your first blood tests are clear, you will likely need repeat testing on a schedule determined by your hematologist to ensure no “hidden” clone is emerging [8][9]. Treatment is most effective when the underlying source of the protein is identified and targeted early [6].

Common questions in this guide

What does monoclonal or polyclonal mean in immunotactoid glomerulopathy?
Monoclonal ITG means the deposits contain one light-chain type, suggesting that one group of abnormal B cells or plasma cells is making the protein. Polyclonal ITG contains a mixture of light chains and is more often associated with autoimmune disease, chronic infection such as Hepatitis C, or broad immune activation. Both patterns require appropriate evaluation.
Why do I need to see a hematologist for immunotactoid glomerulopathy?
ITG can be the first sign that abnormal proteins are being made by the bone marrow or immune system. A hematologist looks for conditions such as chronic lymphocytic leukemia, small lymphocytic lymphoma, multiple myeloma, or monoclonal gammopathy of renal significance, and the referral does not by itself mean you have blood cancer.
Which tests look for a blood-cell cause of ITG?
Doctors may use serum and urine protein electrophoresis with immunofixation to look for an M-protein, a serum free light-chain test to measure kappa and lambda, and flow cytometry to look for a cloned cell population. Depending on the findings, a bone marrow biopsy or imaging may also be needed.
What does MGRS mean in someone with ITG?
MGRS means a small group of abnormal blood cells makes a protein that harms the kidneys but does not meet criteria for a blood cancer that would otherwise require its own treatment. It can still be treated because protecting kidney function is important.
Can my first blood tests be normal even if I have monoclonal ITG?
Yes. The abnormal group of cells may be too small for current blood, marrow, or imaging tests to detect, so a negative first workup does not always rule it out. Your hematologist may recommend repeat testing because a related blood disorder can become detectable later.
What symptoms should I report during ITG monitoring?
Tell your care team about new lumps or swollen lymph nodes in the neck, armpits, or groin, as well as unexplained weight loss, heavy night sweats, or persistent fevers. These symptoms can have many causes, but reporting them helps your clinicians decide whether further evaluation is needed.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Immunotactoid glomerulopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my kidney biopsy show 'monoclonal' (monotypic) or 'polyclonal' deposits?
  2. 2.What was the result of my serum and urine immunofixation tests—did they find a specific 'M-protein'?
  3. 3.If my blood tests are negative now, what is the specific individualized plan for re-testing me?
  4. 4.Based on my biopsy and blood work, do I meet the criteria for Monoclonal Gammopathy of Renal Significance (MGRS)?
  5. 5.Is a bone marrow biopsy necessary at this stage to look for a small clone of cells?
  6. 6.Are my CLL/SLL markers (like flow cytometry) being monitored as part of this evaluation?

References

References (9)
  1. 1

    Immunotactoid glomerulopathy is a rare entity with monoclonal and polyclonal variants.

    Nasr SH, Kudose SS, Said SM, et al.

    Kidney international 2021; (99(2)):410-420 doi:10.1016/j.kint.2020.07.037.

    PMID: 32818517
  2. 2

    Immunotactoid Glomerulopathy.

    Abramson M, Shaikh A

    Advances in kidney disease and health 2024; (31(4)):326-333 doi:10.1053/j.akdh.2024.03.003.

    PMID: 39084758
  3. 3

    Monoclonal gammopathy of renal significance: Spectrum of diseases and approach to a case.

    Tewari R, Chatterjee T, Mendonca S, et al.

    Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2021; (32(2)):298-306 doi:10.4103/1319-2442.335440.

    PMID: 35017322
  4. 4

    Diagnosis of monoclonal immunotactoid glomerulopathy with positive λ chain by immunoelectron microscopy.

    Sugita E, Sonoda H, Ryuzaki M, et al.

    CEN case reports 2023; (12(1)):7-13 doi:10.1007/s13730-022-00714-1.

    PMID: 35699924
  5. 5

    A case report of POEMS syndrome with renal involvement as immunotactoid glomerulopathy.

    Wang Y, Yan Y, Sui Z, et al.

    Medicine 2018; (97(9)):e9920 doi:10.1097/MD.0000000000009920.

    PMID: 29489695
  6. 6

    Results of a nation-wide cohort study suggest favorable long-term outcomes of clone-targeted chemotherapy in immunotactoid glomerulopathy.

    Javaugue V, Dufour-Nourigat L, Desport E, et al.

    Kidney international 2021; (99(2)):421-430 doi:10.1016/j.kint.2020.06.039.

    PMID: 32739419
  7. 7

    Renal manifestations of MGUS.

    Bridoux F, Nasr SH, Arnulf B, et al.

    Hematology. American Society of Hematology. Education Program 2024; (2024(1)):489-498 doi:10.1182/hematology.2024000573.

    PMID: 39644070
  8. 8

    A case report of unusually long lag time between immunotactoid glomerulopathy (itg) diagnosis and diffuse large B-cell lymphoma (DLBCL) development.

    Khandelwal A, Trinkaus MA, Ghaffar H, et al.

    BMC nephrology 2016; (17(1)):140 doi:10.1186/s12882-016-0349-9.

    PMID: 27686684
  9. 9

    Immunotactoid glomerulopathy - an enigmatic case in the setting of nodal marginal zone lymphoma and systemic sclerosis sine scleroderma.

    Mohamed MW, Al-Hammadi M, Hussein AM, et al.

    BMC nephrology 2022; (23(1)):103 doi:10.1186/s12882-022-02730-w.

    PMID: 35291980

This page is for informational purposes only and does not constitute medical advice. Your nephrologist and hematologist can interpret your kidney biopsy, blood tests, and need for follow-up in the context of your specific situation.